|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2005
gptkb:FDA
|
|
gptkbp:atccode
|
L04 AX03
|
|
gptkbp:brand
|
gptkb:Revlimid
|
|
gptkbp:can_be_combined_with
|
gptkb:bortezomib
gptkb:dexamethasone
gptkb:pomalidomide
|
|
gptkbp:casnumber
|
59167-17-8
|
|
gptkbp:category
|
gptkb:X
|
|
gptkbp:chemical_formula
|
C13 H13 N3 O3
|
|
gptkbp:class
|
imidazole derivative
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
|
|
gptkbp:developed_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:discovery_year
|
gptkb:2000
|
|
gptkbp:drug_interactions
|
gptkb:warfarin
live vaccines
other immunosuppressants
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lenalidomide
|
|
gptkbp:indication
|
gptkb:relapsed_or_refractory_multiple_myeloma
first-line treatment for multiple myeloma
maintenance therapy for multiple myeloma
treatment of myelodysplastic syndromes with deletion 5q
|
|
gptkbp:is_monitored_by
|
liver function tests
renal function
complete blood count
|
|
gptkbp:lifespan
|
3 to 5 hours
|
|
gptkbp:marketed_as
|
gptkb:Revlimid
|
|
gptkbp:mechanism_of_action
|
immunomodulatory agent
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
inhibits angiogenesis
enhances T-cell and NK-cell activity
modulates cytokine production
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
constipation
thrombocytopenia
venous thromboembolism
neutropenia
secondary malignancies
|
|
gptkbp:used_for
|
gptkb:myelodysplastic_syndromes
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Pomalidomide
gptkb:Thalidomide
gptkb:Revlimid
gptkb:Pomalyst
gptkb:Thalomid
|
|
gptkbp:bfsLayer
|
5
|